Rising vet bills drive more Americans to pet insurance

About 7 million U.S. pets—more than 4% of the total—had insurance coverage in 2025, up 9% year over year and 76% over five years. Pet insurance premiums are projected to rise 17% to $6.4 billion in 2026 as advanced veterinary care pushes costs higher; veterinary-service prices increased 4.6% year over year in September 2026. Trupanion reported nearly 40% growth in net subscription pet additions in Q2, while Embrace said its average claim rose 6.9% to $432.

Analysis

The second-order effect is not simply more insured pets: insurance can reduce owners’ point-of-care price sensitivity, supporting utilization of diagnostics and therapies, while shifting medical-cost inflation onto insurers. That favors IDEXX Laboratories (IDXX) and Zoetis (ZTS) if added coverage translates into incremental testing and treatment; however, insurance can also expose owners to deductibles, exclusions and reimbursement limits, so higher enrollment does not guarantee proportional utilization.

Trupanion (TRUP) faces the less comfortable side of the same mechanism. Faster additions help its premium base, but claims inflation can outrun repricing, especially if policyholders select coverage when pets are older or already at elevated risk. Watch claim severity and retention alongside additions—not enrollment growth alone. Veterinary capacity, labor and supply costs are potential constraints on both treatment volumes and insurer economics.

Near term, this is a modest sector tailwind, not a standalone catalyst for a multiple re-rating. Over 1–3 months, company disclosures on IDXX diagnostic growth, ZTS product demand, and TRUP claims trends matter more than industry premium forecasts. Over 6–18 months, penetration could structurally widen the addressable market, but competition, treatment affordability and insurer pricing discipline determine who captures the economics.

Contrarian point: coverage growth may be less bullish for insurers than for care suppliers. There is insufficient valuation, price and earnings-sensitivity data to justify a fresh IDXX entry or numeric stop; the promotional chart language in the article is not evidence of a setup.

Key Decisions for Investors

• No immediate trade from this article alone. For IDXX, consider a long only after confirming current valuation and that diagnostic revenue or test volume is accelerating; define entry and stop from the live chart rather than inventing levels here.
• Treat TRUP as a claims-inflation watch, not a buy based on subscription additions. Reassess after its next results: improving additions with stable claim severity supports the thesis; claim costs outpacing premium growth or weakening retention falsifies it.
• Keep ZTS on the beneficiary list, but verify product-level demand and competitive trends before adding exposure; broader access to care does not establish incremental sales for any one therapy.
• Monitor veterinary-service inflation, insurer premium actions, coverage terms and IDXX diagnostic growth over the next 1–3 months. A sustained rise in claims without commensurate repricing would favor care suppliers over insurers; evidence of utilization stagnation despite coverage growth would weaken the sector thesis.